1080623-43-3Relevant articles and documents
Asymmetric Synthesis of a Potent HIV-1 Integrase Inhibitor
Kuethe, Jeffrey T.,Humphrey, Guy R.,Journet, Michel,Peng, Zhihui,Childers, Karla G.
, p. 10256 - 10265 (2016)
The development of a practical asymmetric total synthesis of the potent HIV-1 integrase inhibitor 5 is described. Key transformations include construction of the naphthridine core in a highly efficient manner followed by cyclization of the 8-membered ring. Control of the atropisomers of intermediates and final compound 5 is also described.
Discovery of 2-Pyridinone Aminals: A Prodrug Strategy to Advance a Second Generation of HIV-1 Integrase Strand Transfer Inhibitors
Raheem, Izzat T.,Walji, Abbas M.,Klein, Daniel,Sanders, John M.,Powell, David A.,Abeywickrema, Pravien,Barbe, Guillaume,Bennet, Amrith,Clas, Sophie-Dorothee,Dubost, David,Embrey, Mark,Grobler, Jay,Hafey, Michael J.,Hartingh, Timothy J.,Hazuda, Daria J.,Miller, Michael D.,Moore, Keith P.,Pajkovic, Natasa,Patel, Sangita,Rada, Vanessa,Rearden, Paul,Schreier, John D.,Sisko, John,Steele, Thomas G.,Truchon, Jean-Fran?ois,Wai, John,Xu, Min,Coleman, Paul J.
supporting information, p. 8154 - 8165 (2015/11/09)
The search for new molecular constructs that resemble the critical two-metal binding pharmacophore required for HIV integrase strand transfer inhibition represents a vibrant area of research within drug discovery. Here we present the discovery of a new class of HIV integrase strand transfer inhibitors based on the 2-pyridinone core of MK-0536. These efforts led to the identification of two lead compounds with excellent antiviral activity and preclinical pharmacokinetic profiles to support a once-daily human dose prediction. Dose escalating PK studies in dog revealed significant issues with limited oral absorption and required an innovative prodrug strategy to enhance the high-dose plasma exposures of the parent molecules.
Crystalline forms of an HIV integrase inhibitor
-
, (2008/12/08)
Crystalline forms of a hexahydro-diazocinonaphthyridine trione compound are disclosed. The compound and its crystalline forms thereof are HIV integrase inhibitors useful for the prophylaxis or treatment of HIV infection or for the prophylaxis, treatment or delay in the onset or progression of AIDS.